Efficacy and safety of tyrosine kinase inhibitor dasatinib plus chemotherapy in the treatment of childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
- Author:
Ye GUO
1
;
Tian-Feng LIU
;
Wen-Yu YANG
;
Shu-Chun WANG
;
Min RUAN
;
Xiao-Juan CHEN
;
Li ZHANG
;
Fang LIU
;
Yao ZOU
;
Xiao-Fan ZHU
Author Information
1. Diagnostic and Therapeutic Center of Children's Blood Disease, Institute of Hematology, Blood Disease Hospital, Chinese Academy of Medical Sciences, Tianjin 300020, China.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
administration & dosage;
Child;
Dasatinib;
Female;
Humans;
Male;
Molecular Targeted Therapy;
Neoplasm, Residual;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
drug therapy;
Protein Kinase Inhibitors;
administration & dosage;
Protein-Tyrosine Kinases;
antagonists & inhibitors;
Pyrimidines;
administration & dosage;
adverse effects;
Thiazoles;
administration & dosage;
adverse effects
- From:
Chinese Journal of Contemporary Pediatrics
2015;17(6):634-637
- CountryChina
- Language:Chinese
